india
Karnataka Urges Centre to Extend Price Caps Beyond Cancer Drugs to Other High-Cost Life-Saving Medicines
The Hindu•Published: Oct 10, 2026 02:18 PM IST
Read full source articleShare:
Karnataka has urged the Union government to extend price-control measures beyond cancer drugs to other expensive life-saving medicines used for cardiac and kidney conditions. The appeal follows the National Pharmaceutical Pricing Authority's decision to approve capping trade margins on non-scheduled anti-cancer medicines at 30% of their maximum retail price.
- Trade Margin Caps: The NPPA approved capping trade margins on certain non-scheduled anti-cancer drugs at 30% of their MRP, potentially reducing prices by 20% to 70%.
- State-Level Findings: Karnataka's inspection uncovered massive price mark-ups across 253 medicines and consumables, prompting state authorities to push for national-level reform.
- Billing Transparency: Karnataka issued an advisory circular requiring healthcare institutions to disclose both landing costs and MRPs in patient bills starting November 1.
The Context & Background
The push for broader price regulation comes as the Supreme Court questions why essential medicine mark-ups cannot be strictly limited. Karnataka aims to ensure that price rationalization delivers direct financial relief to patients burdened by astronomical treatment costs.
Why it matters:Expanding price caps from cancer treatments to cardiac and kidney medications could substantially reduce healthcare financial burdens for millions of patients. If adopted nationally, these measures would curb profiteering and ensure greater pricing transparency across India's healthcare system.
Enjoyed this 2-minute breakdown?
Share it with your colleagues and friends!
Share:
Original Sources & Coverage (1)
This event has been analyzed and clustered from the following reporting outlets. Click to read their direct coverage:
